Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the ...

*仅供医学专业人士阅读参考 欧盟CHMP建议批准Beyfortus(nirsevimab)用于预防婴儿RSV疾病· 其批准意见是基于Beyfortus临床试验结果证实，在RSV流行季单剂 ...

Beyfortus是为所有婴幼儿设计的长效抗体疗法，从婴幼儿出生到第一个RSV季节只需一剂就能预防与RSV感染相关的疾病。 作为一种单克隆抗体药物 ...

Beyfortus将成为美国纳入疾控中心疫苗管理的长效单克隆抗体，以满足RSV预防的迫切需求。 Beyfortus是美国批准用于保护所有婴儿的RSV预防手段，推荐用于8个月以下所有婴儿，将于2023-2024年RSV流行季前上市。

此次FDA批准的Beyfortus疗法是在三项临床试验数据基础上作出的决定。 这些试验纳入了近4000名婴儿。

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

钛媒体App 7月22日消息，赛诺菲公司同意以高达16亿美元的价格收购英国生物技术公司Vicebio Ltd.，从而获得了实验性疫苗以及一种能加快疫苗研发进程的技术。赛诺菲首席执行官Paul Hudson正在寻找与赛诺菲现有产品相契合的创新方案，而Vicebio的实验性疫苗旨在预防多种呼吸系统疾病，包括呼吸道合胞病毒(RSV)，这也是赛诺菲新疗法Beyfortus所针对的疾病。（广角观察）返回搜狐 ...

BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...

This Tuesday, the Health Ministry will begin training medical teams ahead of a historic campaign to protect all Israeli ...

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.

Beyfortus is supplied as a 50mg/0.5mL and 100mg/mL prefilled syringe. The product is expected to be available for the upcoming 2023-2024 RSV season.